Zacks Investment Research
02 Feb 2026, 15:55 UTC · 41w ago
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade
Impact · against what's priced in
The article provides a bullish outlook for KalVista Pharmaceuticals based on consensus analyst price targets and earnings revisions. While the potential upside is significant, the information is primarily a synthesis of existing analyst views rather than a new fundamental catalyst.
- KALV+0.40
No priced-in read yet





